phase readout

NCT06649344: A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes

COMPLETEDupdated 12m ago

community read0 votes

Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.. Phase: PHASE3. Conditions: Type 2 Diabetes

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

last refreshed 12m ago

Found something off?